Combination Antibody Therapy Market - High Growth by 2016 - 2022
Growth for combination antibody treatment market is anticipated to gain traction in near future due to the above mentioned factors. Growth for combination antibody treatment market is anticipated to gain traction in near future due to the above mentioned factors.
P e r s i s t e n c e M a r k e t R e s e a r c h About Us Persistence Market Research (PMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Each PMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With a wider scope and stratified research methodology, our syndicated reports strive to serve clients and satisfy their overall research requirement. Copyright © 2015 Persistence Market Research All Rights Reserved. This document contains highly confidential information and is the sole property of PMR. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of PMR. Combination Antibody Therapy Market, 2016 - 2022 Page |
P e r s i s t e n c e M a r k e t R e s e a r c h Report Media Releases Combination Antibody Therapy Market - High Growth by 2016 - 2022 Combination antibody therapy has gained significant recognition in past two decades. It is now a preferred drug treatment for cancers such as lymphomas and solid tumors. Antibodies for modulating immune system has also achieved a significant success clinically. Combination antibody therapy are crucial strategies for treating patients suffering from hematological malignancies and solid tumors. This therapy for tumors is based on the fundamentals of cancer cell’s antigen expression. Combination antibody therapy can function through mediating changes in antigen or receptor functions or modulating the immune system or administering a drug that becomes temporarily united with the antibody, for targeting a specific antigen. According to the journal of oncology (JCO) it has been concluded that a combination of epratuzumab with rituximab was tolerable and had substantial effect in Non-Hodgkin's Lymphoma (NHL). Nonetheless, auto immune disease such as rheumatoid arthritis can be treated by combination of alpha monoclonal antibody with low dose weekly of methotrexate. Additive effect of Rituxan anti-CD20 chimeric antibody with low dose chemotherapy can be effective in B-Cell Lymphoma. Request to view TOC : http://www.persistencemarketresearch.com/toc/11740 The particular nature of the combination antibody therapy has led to more targeted and specific treatment of the cancer and tumor. Hence, become an attractive treatment in recent years due to its non-chemotherapy nature, which in turn gives a safe and secure process of killing the cancer and tumor cells. Growth for combination antibody treatment market is anticipated to gain traction in near future due to the above mentioned factors. Owing to the ability of combination antibodies to specifically target tumor cells and cancer cells has been crucial for the advancement of monoclonal antibodies combination therapy so far due to that it is expected that the CAGR for combination antibody therapy market is tend to expand in near future. Combination antibody therapy market is anticipated to grow on the backdrop of increased effort for developing dual targeting of tumor antigens such as bi-specific ADC’s and novel strategies such as masked antibodies. Requirement of safe and chemotherapy-free cancer treatments have led towards rise in demand for combination antibody therapy. Major part of the demand is expected to be under chronic lymphocytic leukemia. However, over the year significant number of antibodies and immune system modulators have been introduced in various other cancer treatments, which has shown positive effects of disease disposal. The more convenient way for drug administration has empowered the growth of these type of cancer treatments, which further offers more patient compliance. Furthermore, the rise in prevalence of cancer around the globe has been a positive sign for combination antibody therapy market that in turn is expected to underpin the growth in use of combination therapy. Global market for Combination antibody therapy is segmented on the basis of disease, basis of drugs, route of administration and end user: Segmentation by Disease o Cancer o Tumor o Auto-immune disorder Segmentation by Drugs o Nivolumab and Ipilimumab o Trastuzumab and Pertuzumab o Rituximab and Apolizumab o Ofatumumab, and Obinutuzumab Combination Antibody Therapy Market, 2016 - 2022 Page |
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
About Us<br />
Persistence <strong>Market</strong> Research (PMR) is a market intelligence company, providing global business information<br />
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking<br />
insight for thousands of decision makers. We have an experienced team of Analysts, Researchers,<br />
and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze<br />
information. Our business offerings represent the latest and the most reliable information indispensable for<br />
businesses to sustain a competitive edge.<br />
Each PMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical,<br />
energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports<br />
provide in-depth analysis and deep segmentation to possible micro levels. With a wider scope and stratified<br />
research methodology, our syndicated reports strive to serve clients and satisfy their overall research<br />
requirement.<br />
Copyright © 2015 Persistence <strong>Market</strong> Research<br />
All Rights Reserved. This document contains highly confidential information and is the sole property of PMR.<br />
No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of PMR.<br />
<strong>Combination</strong> <strong>Antibody</strong> <strong>Therapy</strong> <strong>Market</strong>, <strong>2016</strong> - <strong>2022</strong> Page |
Change language